Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
172M
-
Number of holders
-
128
-
Total 13F shares, excl. options
-
111M
-
Shares change
-
+19.2M
-
Total reported value, excl. options
-
$3.41B
-
Value change
-
+$589M
-
Put/Call ratio
-
13.86
-
Number of buys
-
83
-
Number of sells
-
-38
-
Price
-
$30.71
Significant Holders of Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) as of Q4 2021
158 filings reported holding RLAY - Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2021.
Relay Therapeutics, Inc. - Common Stock, par value $0.0001 per share (RLAY) has 128 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 111M shares
of 172M outstanding shares and own 64.63% of the company stock.
Largest 10 shareholders include SB INVESTMENT ADVISERS (UK) LTD (27.9M shares), FMR LLC (16.2M shares), VANGUARD GROUP INC (6.2M shares), BlackRock Inc. (5.99M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.16M shares), Bellevue Group AG (4.11M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (4.03M shares), Casdin Capital, LLC (3.86M shares), JPMORGAN CHASE & CO (3.37M shares), and STATE STREET CORP (3.19M shares).
This table shows the top 128 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.